Canada-based Spektus Pharma Inc. and Austria-based GEBRO Holding GmbH have entered into a global commercialisation partnership for ActraFlex®, a twice-daily extended-release formulation of tramadol and paracetamol developed for pain management.
The collaboration combines Spektus Pharma’s proprietary AmyloFlex® drug-delivery technology with GEBRO’s established Diliban® brand and expertise in pain management. Through this partnership, both companies aim to expand ActraFlex® across Europe, the Americas and selected international markets.
Partnership to Expand ActraFlex® Across Global Markets
Under the agreement, GEBRO will manage the commercialisation and supply of ActraFlex® across Europe and selected rest-of-the-world (RoW) markets, with Spain serving as its primary market due to the company’s established regulatory and commercial presence through Diliban®.
Meanwhile, Spektus Pharma will lead commercialisation and supply across North America, South America and selected international markets through its network of regional pharmaceutical partners. Both companies will oversee regulatory and commercial introductions within their respective territories, supported by a shared product platform and global commercialisation strategy. However, the companies have not disclosed the financial terms of the agreement.
Extended-Release Formulation Combines Two Technologies
ActraFlex® combines tramadol and paracetamol in a twice-daily extended-release formulation. It uses Spektus Pharma’s patented AmyloFlex® drug-delivery platform alongside GEBRO’s established Diliban® product. The formulation is designed to provide sustained drug release and a convenient twice-daily dosing schedule for pain management.
According to Zarvaan Merchant, CEO of Spektus Pharma, the partnership demonstrates the potential of AmyloFlex® technology to develop differentiated specialty medicines from established pharmaceutical products. He also highlighted opportunities to expand ActraFlex® across the Americas and selected markets in Africa and Asia.
Similarly, Christian Kollenz, Managing Director of GEBRO Holding, said the collaboration combines GEBRO’s experience in pain management and its established Diliban® presence in Europe with Spektus Pharma’s international commercialisation network. As per the company press release, the partnership aims to expand the regulatory approval, supply and global commercialisation of ActraFlex® across multiple international markets.